Journal Information
Vol. 45. Issue S3.
XIV Eurasian Hematology Oncology Congress
Pages S46 (October 2023)
Share
Share
Download PDF
More article options
Vol. 45. Issue S3.
XIV Eurasian Hematology Oncology Congress
Pages S46 (October 2023)
Pediatric Oncology Abstract CategoriesNeuroblastoma PP 33
Full text access
NEUROBLASTOMA AND ASSOCIATED DISORDERS, A SINGLE CENTER EXPERIENCE
Visits
336
Arzu Yazal Erdem1, Selma Çakmakcı1, Seda Şahin1, Derya Özyörük1, Neriman Sarı1, Suna Emir2, İnci Ergürhan İlhan1
1 Ankara Bilkent City Hospital
2 Atılım Üniversitesi Tıp Fakültesi
This item has received
Article information
Abstract
Full Text
Download PDF
Statistics
Tables (1)
Special issue
This article is part of special issue:
Vol. 45. Issue S3

XIV Eurasian Hematology Oncology Congress

More info
Objective

The genetic factors involved in development of neuroblastoma are not yet well understood. The most common somatic genomic alterations in neuroblastomas are recurrent chromosomal copy number alterations. In addition a number of genes with germline mutations commonpolymorphisms have been identified that raise the risk of developing neuroblastoma, it is unclear what role they play. With this aim, we investigated the syndromes, diseases and abnormalities accompanying our neuroblastoma patients.

Case report

Methodology

The files of patients with neuroblastoma in Ankara Dışkapı Children's Hospital, Ankara Oncology Hospital, and Ankara City Hospital between 1993 and 2023 were retrospectively analyzed. Data collected from the files included the age, sex, pathological findings, physical examination findings, imaging findings and follow-up time.

Results

The files of 194 patients diagnosed with neuroblastoma were retrospectively evaluated, and distinct abnormalities and syndromes were noted in 11 patients (0.56%). The patient characteristics were presented in the Table1. Heterochromia have been known in association with NB. Neuroblastomas are rare per se in the setting of NF1 (0.2% of all NBs) and even if compared to the overall frequency of malignancies in NF1 (i.e., 14.7%). Paraneoplastic syndromes including opsoclonus-myoclonus-ataxia syndro

Conclusion

Here we report on a new patient with Kabuki syndrome and a germline variant in KMT2D who developed a neuroblastoma. Including our patient literature review identifed 19 patients with Kabuki syndrome and a malignancy. Although we found no strong arguments pointing towards KS as a tumor predisposition syndrome, based on the small numbers any relation cannot be fully excluded. As the genetics of neuroblastoma become understood in syndromic patients, steps towards intervention may be successful.

Full Text

Patient no  Age at diagnosis/gender  Syndrome/disease  Histology  Follow-up time (year) 
1  8y,F  MMR+NF type 1  GNB 
2  1,5y, M  Heterochromia  NB  13 
3  2,5y, F  Heterochromia  NB  13 
4  2y, M  Hypotonic infant  GNB 
5  12y, F  Hereditary sferocytosis  GN  12 
6  1y, M  Vertebral fusion anomalies, syndactily  NB  3,5 
7  9y, F  Congenital C3 deficiency  GNB 
8  1.5y, F  Congenital adrenal hyperplasia  GNB  2,5 
9  7y, F  Kabuki syndrome  GNB  0,25 
10  2y, F  OMAS  GNB 
11  1y, M  OMAS  GNB  12 

Abbreviations:

GN: ganglioneuroma

GNB: ganglioneuroblastoma

NB: neuroblastoma

NF: neurofibromatosis

MMR: mental motor retardation

OMAS: opsoclonus myoclonus ataxia syndrome

Idiomas
Hematology, Transfusion and Cell Therapy
Article options
Tools